



Cyclacel Pharmaceuticals, Inc.
Investor Relations Department
200 Connell Drive, Suite 1500
Berkeley Heights, NJ 07922
United States

[Visit IR website](#)
[Sign-up for email alerts](#)

NASDAQ: CYCC ¹

Last Trade:	1.65
Trade Time:	4:00 PM ET Aug 22, 2017
Change:	-0.03 (1.786%)
Day Range	1.61 - 1.68
52-Week Range	1.56 - 10.90
Volume	245,476
Market Cap. (\$M)	18.810
Shares Out (M)	11.400

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

We are a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Our strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Aug 9, 2017*
[Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results](#)
- Aug 7, 2017*
[Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression](#)
- Aug 2, 2017*
[Cyclacel Pharmaceuticals to Release Second Quarter 2017 Financial Results](#)
- Jul 21, 2017*
[Cyclacel Announces Closing of \\$15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option](#)
- Jul 19, 2017*
[Cyclacel Announces Pricing of \\$13.2 Million Underwritten Public Offering](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

- Mar 31, 2017*
[Annual Report \(10-K\)](#)
- Apr 12, 2017*
[Definitive Proxy Statement](#)
- Aug 10, 2017*
[Quarterly Report \(10-Q\)](#)
- May 12, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 14, 2016*
[Quarterly Report \(10-Q\)](#)